

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest developments related to the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company’s B2C and B2B sales business has grown rapidly and steadily since the beginning of 2026. According to the Company’s preliminary statistics, as of the date of this announcement, the cumulative realized sales revenue for the year has exceeded the sales revenue for the whole year of 2025.

As of the date of this announcement, the Company’s sales revenue for the year has reached approximately RMB34 million, exceeding the total sales revenue of RMB32.68 million for the whole last year, and is expected to complete the annual target of exceeding RMB150 million, mainly comprising B2C domestic e-commerce sales, overseas e-commerce sales and B2B raw material sales.

In the B2C domestic e-commerce segment, the sales revenue in the first quarter of this year increased by 25 times compared to the same period last year. In particular, since the launch of the Company’s in-house live-streaming sales business 5 months ago, the sales revenue has continued to grow, with an average daily sales of nearly RMB100,000 this month, setting a record for a single-day gross merchandise value (GMV) of RMB400,000.

In the B2C overseas e-commerce segment, the sales revenue in the first quarter of this year increased by 150% compared to the same period last year.

In the B2B raw material sales segment, the sales revenue in the first quarter of this year was RMB3.44 million, compared with zero in the same period last year, which also far exceeded the sales revenue for the whole last year.

The Company plans to use the cash flow generated from the cosmetic products and raw materials business to fund the development and commercialization of the Company's core products KX-826 and GT20029 and other pipeline products (the “**Listing Business**”). Meanwhile, the Company will continue to adhere to the established policy of its listing business.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 20 April 2026

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Yunfei Chen and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*